Cargando…
Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have shown to prevent heart failure progression, although the mechanisms remain poorly understood. Here we evaluated the effect of empagliflozin (EMPA, SGLT2i) in cardiac remodeling after myocardial infarction, the interplay with diabetes status an...
Autores principales: | Asensio Lopez, Maria del Carmen, Lax, Antonio, Hernandez Vicente, Alvaro, Saura Guillen, Elena, Hernandez-Martinez, Antonio, Fernandez del Palacio, Maria Josefa, Bayes Genis, Andoni, Pascual Figal, Domingo A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419540/ https://www.ncbi.nlm.nih.gov/pubmed/32782412 http://dx.doi.org/10.1038/s41598-020-70454-8 |
Ejemplares similares
-
Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
por: del Carmen Asensio Lopez, Maria, et al.
Publicado: (2020) -
The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI
por: Asensio-Lopez, Maria Carmen, et al.
Publicado: (2021) -
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis
por: Lax, Antonio, et al.
Publicado: (2023) -
GTP Cyclohydrolase
1/Tetrahydrobiopterin Counteract
Ferroptosis through Lipid Remodeling
por: Kraft, Vanessa A. N., et al.
Publicado: (2019) -
Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers
por: Mencacci, Niccolò E., et al.
Publicado: (2014)